We are live on ! Find out more
SRRA

Sierra Oncology, Inc. Common Stock
SRRA

Delisted

SRRA was delisted on the 30th of June, 2022.

Back to rankings

75 hedge funds and large institutions have $641M invested in Sierra Oncology, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 18 increasing their positions, 13 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

537% more call options, than puts

Call options by funds: $4.1M | Put options by funds: $644K

290% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 10

140% more capital invested

Capital invested by funds: $267M → $641M (+$374M)

63% more funds holding

Funds holding: 46 → 75 (+29)

60% more funds holding in top 10

Funds holding in top 10: 5 → 8 (+3)

38% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 13

Holders
75
Holders Change
+29
Holders Change %
+63.04%
% of All Funds
1.18%
Holding in Top 10
8
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+60%
% of All Funds
0.13%
New
39
Increased
18
Reduced
13
Closed
10
Calls
$4.1M
Puts
$644K
Net Calls
+$3.46M
Net Calls Change
+$3.46M

Top Buyers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
+$40.5M
2
PHS
PFM Health Sciences
California
+$30.5M
3
O
OrbiMed
New York
+$14M
4
Citadel Advisors
Citadel Advisors
Florida
+$13.4M
5
Goldman Sachs
Goldman Sachs
New York
+$12.7M

Top Sellers

Rank Fund Capital Flow
1
FM
Frazier Management
Washington
-$34.7M
2
DTC
Deep Track Capital
Connecticut
-$13.2M
3
IC
Ikarian Capital
Texas
-$10.1M
4
NLVP
New Leaf Venture Partners
New York
-$8.15M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$6.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
26
Millennium Management
New York
$4.24M +$3.79M +132,187 New
SSA
27
Schonfeld Strategic Advisors
New York
$4.05M +$3.63M +126,500 New
NLVP
28
New Leaf Venture Partners
New York
$4.02M -$8.15M -284,100 -69%
Walleye Capital
29
Walleye Capital
New York
$3.82M +$3.42M +119,090 New
Morgan Stanley
30
Morgan Stanley
New York
$3.05M +$2.44M +84,950 +832%
Renaissance Technologies
31
Renaissance Technologies
New York
$2.96M -$533K -18,561 -17%
JSC
32
Jackson Square Capital
California
$2.85M +$2.55M +88,825 New
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
$2.13M +$1.91M +66,400 New
EGI
34
EAM Global Investors
California
$2.11M +$1.89M +65,846 New
DMKJ
35
David M. Knott Jr
$1.79M +$1.6M +55,758 New
FM
36
Frazier Management
Washington
$1.75M -$34.7M -1,210,207 -96%
NFGH
37
Nan Fung Group Holdings
Hong Kong
$1.7M – – –
Fidelity Investments
38
Fidelity Investments
Massachusetts
$1.67M +$1.49M +52,000 New
SCM
39
Sio Capital Management
New York
$1.56M -$1.34M -46,682 -49%
Ensign Peak Advisors
40
Ensign Peak Advisors
Utah
$1.56M +$1.4M +48,657 New
CSS
41
Cubist Systematic Strategies
Connecticut
$1.45M +$1.29M +45,130 New
Dimensional Fund Advisors
42
Dimensional Fund Advisors
Texas
$1.42M +$141K +4,899 +12%
PPA
43
Parametric Portfolio Associates
Washington
$1.4M +$1.25M +43,721 New
FAM
44
Fred Alger Management
New York
$1.28M +$1.14M +39,878 New
Northern Trust
45
Northern Trust
Illinois
$1.21M -$27.6K -962 -2%
Jane Street
46
Jane Street
New York
$1.06M +$951K +33,131 New
IHAM
47
Integral Health Asset Management
New York
$962K +$861K +30,000 New
BFM
48
Boothbay Fund Management
New York
$914K -$1.11M -38,773 -58%
AI
49
Atom Investors
Texas
$802K +$718K +25,008 New
Connor, Clark & Lunn Investment Management (CC&L)
50
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$791K +$708K +24,685 New
1
2
3 4

SRRA Hedge Fund Activity: Q1 2022 in Review

75 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Sierra Oncology, Inc. Common Stock (SRRA) for Q1 2022, worth a combined $641M — up 140% from $267M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new SRRA positions and 10 closed out — a net gain of 29 holders — while 18 added to existing stakes and 13 trimmed.

The largest buyer was Vivo Capital, adding an estimated $40.5M. The largest seller was Frazier Management, cutting an estimated $34.7M.

  • 75 institutional investors held Sierra Oncology, Inc. Common Stock (SRRA) as of Q1 2022, up from 46 in Q4 2021.
  • Funds reported $641M of Sierra Oncology, Inc. Common Stock stock for Q1 2022, up 140% quarter-over-quarter.
  • 39 funds opened new Sierra Oncology, Inc. Common Stock positions in Q1 2022 and 10 closed out, a net change of +29 holders.
  • The largest Sierra Oncology, Inc. Common Stock buyer in Q1 2022 was Vivo Capital, an estimated $40.5M added.
  • The largest Sierra Oncology, Inc. Common Stock seller in Q1 2022 was Frazier Management, an estimated $34.7M sold.

Based on aggregated 13F filings for Q1 2022.